SEARCH

SEARCH BY CITATION

References

  • AGURELL, S., HALLDIN, M., LINDGREN, J.-E., OHLSSON, A., WIDMAN, M., GILLESPIE, H. & HOLLISTER, L. (1986). Pharmacokinetics and metabolism of Δ1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol. Rev., 38, 2143.
  • BROWN, A. & WISE, A. (2003). Identification of modulators of gpr55 activity. US Patent Document Number 20030113814 at http://appft1.uspto.gov/netahtml/PTO/search-bool.html.
  • DEVANE, W.A., HANUS, L., BREUER, A., PERTWEE, R.G., STEVENSON, L.A., GRIFFIN, G., GIBSON, D., MANDELBAUM, A., ETINGER, A. & MECHOULAM, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 19461949.
  • DI MARZO, V., DE PETROCELLIS, L. & BISOGNO, T. (2005). The biosynthesis, fate and pharmacological properties of endocannabinoids. In: Cannabinoids. Handbook of Experimental Pharmacology. ed. Pertwee, R.G. vol. 168, pp. 147185. Heidelburg: Springer-Verlag.
  • ELSOHLY, M.A. (2002). Chemical constituents of cannabis. In: Cannabis and Cannabinoids. Pharmacology, Toxicology and Therapeutic Potential. eds. Grotenhermen, F. & Russo, E. pp. 2736. New York: Haworth Press Inc.
  • GILL, E.W., PATON, W.D.M. & PERTWEE, R.G. (1970). Preliminary experiments on the chemistry and pharmacology of cannabis. Nature, 228, 134136.
  • HAAGEN-SMIT, A.J., WAWRA, C.Z., KOEPFLI, J.B., ALLES, G.A., FEIGEN, G.A. & PRATER, A.N. (1940). A physiologically active principle from Cannabis sativa (marihuana). Science, 91, 602603.
  • HILLARD, C.J. & JARRAHIAN, A. (2003). Cellular accumulation of anandamide: consensus and controversy. Br. J. Pharmacol., 140, 802808.
  • HOWLETT, A.C. (2005). Cannabinoid receptor signaling. In: Cannabinoids. Handbook of Experimental Pharmacology. ed. Pertwee, R.G. vol. 168, pp. 5379. Heidelburg: Springer-Verlag.
  • HOWLETT, A.C., BARTH, F., BONNER, T.I., CABRAL, G., CASELLAS, P., DEVANE, W.A., FELDER, C.C., HERKENHAM, M., MACKIE, K., MARTIN, B.R., MECHOULAM, R. & PERTWEE, R.G. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev., 54, 161202.
  • LOEWE, S. (1944). Studies on the pharmacology of marihuana. In: The Marihuana Problems in the City of New York, ed. The Mayor's Committee on Marihuana. pp. 149212. Lancaster, PA: The Jaques Cattell Press.
  • LOEWE, S. (1946). Studies on the pharmacology and acute toxicity of compounds with marihuana activity. J. Pharmacol. Exp. Ther., 88, 154161.
  • MECHOULAM, R. (1973). Cannabinoid chemistry. In: Marijuana, ed. Mechoulam, R. pp. 199. New York: Academic Press.
  • MECHOULAM, R. (1986). The pharmacohistory of Cannabis sativa. In: Cannabinoids as Therapeutic Agents, ed. Mechoulam, R. pp. 119. Boca Raton, FL: CRC Press.
  • MECHOULAM, R. & HANUS, L. (2000). A historical overview of chemical research on cannabinoids. Chem. Phys. Lipids, 108, 113.
  • PATON, W.D.M. & PERTWEE, R.G. (1972). Effect of cannabis and certain of its constituents on pentobarbitone sleeping time and phenazone metabolism. Br. J. Pharmacol., 44, 250261.
  • PATON, W.D.M. & PERTWEE, R.G. (1973a). The pharmacology of cannabis in animals. In: Marijuana, ed. Mechoulam, R. pp. 191285. New York: Academic Press.
  • PATON, W.D.M. & PERTWEE, R.G. (1973b). The actions of cannabis in man. In: Marijuana, ed. Mechoulam, R. pp. 287333. New York: Academic Press.
  • PERTWEE, R.G. (1972). The ring test: a quantitative method for assessing the ‘cataleptic’ effect of cannabis in mice. Br. J. Pharmacol., 46, 753763.
  • PERTWEE, R.G. (1988). The central neuropharmacology of psychotropic cannabinoids. Pharmacol. Ther., 36, 189261.
  • PERTWEE, R.G. (1991). Tolerance to and dependence on psychotropic cannabinoids. In: The Biological Bases of Drug Tolerance and Dependence, ed. Pratt, J.A. pp. 231263. London: Academic Press.
  • PERTWEE, R.G. (1997). Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther., 74, 129180.
  • PERTWEE, R.G. (1999). Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem., 6, 635664.
  • PERTWEE, R.G. (2004). The pharmacology and therapeutic potential of cannabidiol. In: Cannabinoids, ed. Di Marzo, V. pp. 3283. New York: Kluwer Academic/Plenum Publishers.
  • PERTWEE, R.G. (2005a). Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci., 76, 13071324.
  • PERTWEE, R.G. (2005b). Pharmacological actions of cannabinoids. In: Cannabinoids. Handbook of Experimental Pharmacology. ed. Pertwee, R.G. vol. 168, pp. 151. Heidelburg: Springer-Verlag.
  • PERTWEE, R.G. (2005c). The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J. (in press).
  • PERTWEE, R.G., FERNANDO, S.R., GRIFFIN, G., ABADJI, V. & MAKRIYANNIS, A. (1995). Effect of phenylmethylsulphonyl fluoride on the potency of anandamide as an inhibitor of electrically evoked contractions in two isolated tissue preparations. Eur. J. Pharmacol., 272, 7378.
  • PERTWEE, R.G., GIBSON, T.M., STEVENSON, L.A., ROSS, R.A., BANNER, W.K., SAHA, B., RAZDAN, R.K. & MARTIN, B.R. (2000). O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties. Br. J. Pharmacol., 129, 15771584.
  • PERTWEE, R.G., STEVENSON, L.A. & GRIFFIN, G. (1993). Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide. Br. J. Pharmacol., 110, 14831490.
  • PRICE, M.R., BAILLIE, G.L., THOMAS, A., STEVENSON, L.A., EASSON, M., GOODWIN, R., MCLEAN, A., MCINTOSH, L., GOODWIN, G., WALKER, G., WESTWOOD, P., MARRS, J., THOMSON, F., COWLEY, P., CHRISTOPOULOS, A., PERTWEE, R.G. & ROSS, R.A. (2005). Allosteric modulation of the cannabinoid CB1 receptor. Mol. Pharmacol., 68, 14847ndash;1495. http://molpharm.aspetjournals.org/cgi/content/abstract/mol.105.016162v1.
  • RINALDI-CARMONA, M., BARTH, F., HÉAULME, M., SHIRE, D., CALANDRA, B., CONGY, C., MARTINEZ, S., MARUANI, J., NÉLIAT, G., CAPUT, D., FERRARA, P., SOUBRIÉ, P., BRELIÈRE, J.C. & LE FUR, G. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett., 350, 240244.
  • ROBSON, P. (2005). Human studies of cannabinoids and medicinal cannabis. In: Cannabinoids. Handbook of Experimental Pharmacology. ed. Pertwee, R.G. vol. 168, pp. 719756. Heidelburg: Springer-Verlag.
  • ROSS, R.A. (2003). Anandamide and vanilloid TRPV1 receptors. Br. J. Pharmacol., 140, 790801.
  • SIM-SELLEY, L.J. (2003). Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit. Rev. Neurobiol., 15, 91119.
  • TANDA, G. & GOLDBERG, S.R. (2003). Cannabinoids: reward, dependence, and underlying neurochemical mechanisms – a review of recent preclinical data. Psychopharmacology, 169, 115134.
  • THOMAS, A., STEVENSON, L.A., WEASE, K.N., PRICE, M.R., BAILLIE, G., ROSS, R.A. & PERTWEE, R.G. (2005). Evidence that the plant cannabinoid Δ9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br. J. Pharmacol., Epub 3 October 2005; doi: 10.1038/sj.bjp.0706414.
  • VAN GAAL, L.F., RISSANEN, A.M., SCHEEN, A.J., ZIEGLER, O. & RÖSSNER, S. (2005). Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet, 365, 13891397.
  • VAUGHAN, C.W. & CHRISTIE, M.J. (2005). Retrograde signalling by endocannabinoids. In: Cannabinoids. Handbook of Experimental Pharmacology. ed. Pertwee, R.G. vol. 168, pp. 367383. Heidelburg: Springer-Verlag.
  • WALKER, J.M. & HOHMANN, A.G. (2005). Cannabinoid mechanisms of pain suppression. In: Cannabinoids. Handbook of Experimental Pharmacology. ed. Pertwee, R.G. vol. 168, pp. 509554. Heidelburg: Springer-Verlag.